These findings open new avenues for research and suggest that therapeutic strategies targeting lysosomal function, specifically modulating cathepsin activity or enhancing sAPP’s interaction with tau and CTSG, may hold promise for treating AD and related neurodegenerative diseases. This evidence concerns the gene MAPT and Alzheimer disease.